|
1
|
Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG and
Kim JW: Response of pigment epithelial detachment to anti-vascular
endothelial growth factor treatment in age-related macular
degeneration. Am J Ophthalmol. 166:112–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ueda K, Zhao J, Kim HJ and Sparrow JR:
Photodegradation of retinal bisretinoids in mouse models and
implications for macular degeneration. Proc Natl Acad Sci USA.
113:6904–6909. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Novais EA, Badaró E, Hirai FE, Jorge FA,
Leal P, Farah ME and Rodrigues EB: Daily optical coherence
tomography examinations after first antivascular endothelial growth
factor injections: an interventional case series. J Ophthalmol.
2016:69718312016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heimes B, Gunnemann F, Ziegler M,
Gutfleisch M, Spital G, Pauleikhoff D and Lommatzsch A: Compliance
of age related macular degeneration patients undergoing anti-VEGF
therapy: analysis and suggestions for improvement. Ophthalmologe.
6:Jun 6–2016.(In German) (Epub ahead of print).
|
|
5
|
Senra H, Ali Z, Balaskas K and Aslam T:
Psychological impact of anti-VEGF treatments for wet macular
degeneration-a review. Graefes Arch Clin Exp Ophthalmol. 4:12–13.
2016.
|
|
6
|
Arias L, Gómez-Ulla F and Ruiz-Moreno JM:
Ranibizumab in monotherapy and combined with photodynamic therapy
for retinal angiomatous proliferation. Clin Ophthalmol. 10:861–869.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wu B, Li J, Lin H and Wu H: Different
strategies for the treatment of age-related macular degeneration in
China: an economic evaluation. J Ophthalmol. 2016:76898622016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scherer KM, Bisby RH, Botchway SW and
Parker AW: New approaches to photodynamic therapy from type I, II
and III to type IV using one or more photons. Anticancer Agents Med
Chem. 13:17–18. 2016.
|
|
9
|
Catchpole T, Daniels T, Perkins J and
Csaky KG: Method development to quantify Bv8 expression in
circulating CD11b+ cells in patients with neovascular
age-related macular degeneration (nvAMD) exhibiting anti-VEGF
refractoriness. Exp Eye Res. 148:45–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Otsuji T, Sho K, Tsumura A, Koike N,
Nishimura T and Takahashi K: Three-year results of a modified
photodynamic therapy procedure (Ironing PDT) for age-related
macular degeneration patients with large lesions. Clin Ophthalmol.
10:431–436. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arnold JJ: Age-related macular
degeneration: anti-vascular endothelial growth factor treatment.
BMJ Clin Evid. 24:07012016.
|
|
12
|
Uzun S and Pehlivan E: Comparison of
intravitreal aflibercept and ranibizumab injections on subfoveal
and peripapillary choroidal thickness in eyes with neovascular
age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol.
2:15–16. 2016.
|
|
13
|
Teper SJ, Nowinska A, Pilat J and Wylegala
E: Photodynamic therapy in VEGF inhibition
non-responders-pharmacogenetic study in age-related macular
degeneration assessed with swept-source optical coherence
tomography. Photodiagn Photodyn Ther. 13:108–113. 2016. View Article : Google Scholar
|
|
14
|
Lee JP, Park JS, Kwon OW, You YS and Kim
SH: Management of acute submacular hemorrhage with intravitreal
injection of tenecteplase, anti-vascular endothelial growth factor
and gas. Korean J Ophthalmol. 30:192–197. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Newman DK: Photodynamic therapy: current
role in the treatment of chorioretinal conditions. Eye (Lond).
30:202–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
MacDonald DA, Martin J, Muthusamy KK, Luo
JK, Pyles E, Rafique A, Huang T, Potocky T, Liu Y, Cao J, et al:
Aflibercept exhibits VEGF binding stoichiometry distinct from
bevacizumab and does not support formation of immune-like
complexes. Angiogenesis. 19:389–406. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Colombeau L, Acherar S, Baros F, Arnoux P,
Gazzali AM, Zaghdoudi K, Toussaint M, Vanderesse R and Frochot C:
Inorganic nanoparticles for photodynamic therapy. Top Curr Chem.
370:113–134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shahin M, Gad MA and Hamza W: Impact of
intravitreal triamcinolone acetonide versus intravitreal
bevacizumab on retrobulbar hemodynamic in patients with diabetic
macular edema. Cutan Ocul Toxicol. 33:49–53. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Toklu Y, Cakmak HB, Raza S, Anayol A, Asik
E and Simşek S: Short-term effects of intravitreal bevacizumab
[Avastin®] on retrobulbar hemodynamics in patients with
neovascular age-related macular degeneration. Acta Ophthalmol.
89:e41–e45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mete A, Saygili O, Mete A, Bayram M and
Bekir N: Effects of intravitreal bevacizumab (Avastin) therapy on
retrobulbar blood flow parameters in patients with neovascular
age-related macular degeneration. J Clin Ultrasound. 38:66–70.
2010.PubMed/NCBI
|
|
21
|
Sakalar YB, Senturk S, Yildirim M,
Keklikci U, Alakus MF and Unlu K: Evaluation of retrobulbar blood
flow by color doppler ultrasonography after intravitreal
ranibizumab injection in patients with neovascular age-related
macular degeneration. J Clin Ultrasound. 41:32–37. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koizumi H, Kano M, Yamamoto A, Saito M,
Maruko I, Kawasaki R, Sekiryu T, Okada AA and Iida T: Short-term
changes in choroidal thickness after aflibercept therapy for
neovascular age-related macular degeneration. Am J Ophthalmol.
159:627–633. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Smith RT: New understanding of age-related
macular degeneration through quantitative autofluorescence. JAMA
Ophthalmol. 134:824–826. 2016. View Article : Google Scholar : PubMed/NCBI
|
